BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR+ NSCLC
BRAF fusion represents an acquired resistance mechanism to osimertinib in EGFR‑mutated NSCLC, and combined EGFR‑MEK inhibition with osimertinib and trametinib may provide clinical benefit.
Despite the efficacy of osimertinib in the first‑line treatment of advanced EGFR‑mutated NSCLC, the development of resistance is nearly inevitable. BRAF mutations and fusions are reported in 1% to 3% of patients with EGFR‑mutated NSCLC receiving osimertinib and represent potential targetable alterations.
Understanding which mechanisms drive acquired resistance to osimertinib can inform subsequent therapy choices and improve clinical outcomes for patients with EGFR‑mutated NSCLC.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT